Apimeds Pharmaceuticals US (APUS) vs Bolt Biotherapeutics (BOLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bolt Biotherapeutics is the larger company by market cap ($8.5 million vs $7.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APUS | BOLT |
|---|---|---|
| Share price | $4.65 | $4.39 |
| Market cap | $7.02M | $8.46M |
| 1-day change | -15.61% | +20.94% |
| YTD return | -66.40% | — |
| 1-year return | -70.53% | — |
| EPS (TTM) | $-36.03 | $-16.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.70 | $7.20 |
| 52-week low | $1.51 | $3.10 |
| Distance from 52-week high | -92.21% | -39.03% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +560.59% |
| Average volume | 3.67M | 26.26K |
| Shares outstanding | 1.51M | 1.93M |
| Employees | — | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apimeds Pharmaceuticals US
APUS stock →Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
APUS vs BOLT FAQ
Which is bigger, Apimeds Pharmaceuticals US or Bolt Biotherapeutics?
Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $8.46M compared with $7.02M for Apimeds Pharmaceuticals US (APUS).
Are Apimeds Pharmaceuticals US and Bolt Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.